Retatrutide has no brand name yet — it's an investigational Eli Lilly drug known as LY3437943. Here's what to know about the retatrutide brand name.
Retatrutide does not have a brand name yet. It is an investigational drug that Eli Lilly is developing for obesity and type 2 diabetes, and it is currently known only by its generic (INN) name, retatrutide, and its internal development code, LY3437943. No trade name has been announced, and the FDA has not approved retatrutide for any human use.
That means every article, forum post, or product listing that promises a 'retatrutide brand name' is either repeating a rumor or selling something that is not an approved medicine.
Does Retatrutide Have a Brand Name Right Now?
No. There is no retatrutide brand name today, because brand names are assigned at approval rather than during clinical testing. The retatrutide generic name is simply retatrutide.
Only two names are in legitimate use for this molecule right now:
- Retatrutide — the international nonproprietary name (INN), which functions as the generic name.
- LY3437943 — Eli Lilly's internal compound code, used in trial documents and scientific papers.
If you are looking for another name for retatrutide, the only accurate answer today is LY3437943. Any consumer-friendly name you see online is speculation, a placeholder, or marketing.
How Other Weight-Loss Drugs Compare
| Generic name | Brand name | Status |
|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | FDA-approved |
| Tirzepatide | Mounjaro, Zepbound | FDA-approved |
| Liraglutide | Victoza, Saxenda | FDA-approved |
| Retatrutide | None announced | Investigational |
Brand names usually arrive years after the generic name first shows up in trials. Tirzepatide was called tirzepatide long before Mounjaro and Zepbound existed, and the same pattern is likely here.
Why Retatrutide Is Still Known Only by Its Generic Name
Pharmaceutical companies generally announce a trade name only when approval is close. Names are tied to trademarks, packaging, insurance negotiations, and marketing budgets, so companies stay quiet until the regulatory path looks solid.
Retatrutide is a triple agonist, meaning it targets GIP, GLP-1, and glucagon receptors at the same time. That makes it a different molecule from tirzepatide, which is a dual GIP/GLP-1 agonist from the same manufacturer.
Because no approved product exists, questions such as how long does retatrutide take to work can only be answered from clinical trial data, not from an FDA-approved label or a pharmacy handout.
What Brand Name Would Retatrutide Get?
Nobody outside Eli Lilly knows the answer. The company has not publicly announced a trade name for retatrutide, and no regulatory filing has revealed one.
Lilly's recent naming style — Mounjaro and Zepbound for tirzepatide — suggests a short, brandable word rather than anything descriptive. Guessing from that pattern is not a prediction.
Treat any headline claiming to reveal the official retatrutide brand as unverified unless it comes directly from Eli Lilly or the FDA.
Is Retatrutide Sold Under Any Brand Today?
No. There is no brand-name or generic retatrutide legally available for human use in the United States.
What circulates online is different. Sellers such as limitless peptides retatrutide listings market the compound as a research chemical, which means it is not manufactured under FDA rules, not tested for sterility, and not intended for human use.
The FDA has warned that compounded or unapproved versions of retatrutide have not been evaluated for safety or effectiveness.
Community threads, including retatrutide trial reddit discussions, often blend real trial findings with personal anecdotes. They can be interesting reading, but they are not medical evidence.
Because there is no approved label, guidance on retatrutide how to inject comes from trial protocols rather than from official patient instructions.
People researching other compounds frequently compare aod 9604 and retatrutide, even though the two sit at very different stages of development and neither should replace care from a clinician.
What to Watch For Before a Name Appears
- Eli Lilly press releases announcing phase 3 results or regulatory submissions
- FDA approval notices and new drug application filings
- Trademark applications filed with the US Patent and Trademark Office
- Peer-reviewed publications in major medical journals
Retatrutide is not FDA-approved for human use in the United States, and no brand name exists in any country.
For now, the only legitimate way to receive retatrutide is through an enrolled clinical trial with proper medical monitoring.
If you are looking for weight-loss treatment today, ask a healthcare professional about approved options and discuss risks, side effects, and interactions openly.
Frequently Asked Questions
Does retatrutide have a brand name?
Not yet. Retatrutide is still an investigational drug, so it has no trade name in any country. Until it is approved, it is identified by its generic name, retatrutide, and by the development code LY3437943.
What is the generic name for retatrutide?
Retatrutide is the generic name — specifically the international nonproprietary name (INN). The other name you will see for the same molecule is LY3437943, which is Eli Lilly's internal development code.
Can I buy retatrutide now?
No legal, FDA-approved retatrutide product is available for sale. Products marketed online as retatrutide are typically research chemicals that are not intended for human use and are not verified for purity or safety. Talk with a healthcare professional about approved alternatives.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.